2021 to 2022 Saw Decrease in Age-Adjusted Death Rate in U.S.
THURSDAY, May 4, 2023 (HealthDay News) — There was a decrease in the age-adjusted death rate from 2021 to 2022, as well as a decrease in the COVID-19 mortality rate, according to research published in the May 5 issue of the U.S. Centers for Disease …
Learn MoreReported Smoking Prevalence Lowest Since 1965
THURSDAY, May 4, 2023 (HealthDay News) — Overall, 18.7 percent of U.S. adults reported currently using any tobacco product in 2021, with most reporting combustible tobacco product use, according to research published in the May 5 issue of the U.S. C…
Learn MoreAdherence to Healthy Lifestyle Cuts Breast Cancer Recurrence, Mortality
THURSDAY, May 4, 2023 (HealthDay News) — Strongest adherence to cancer prevention lifestyle recommendations is associated with reductions in disease recurrence and mortality among patients with high-risk breast cancer, according to a study published …
Learn MoreDiabetes Risk Awareness Not Linked to Risk-Reducing Behavior in Youth
THURSDAY, May 4, 2023 (HealthDay News) — Diabetes risk perception and awareness are not associated with greater engagement in risk-reducing behaviors among U.S. youth aged 12 to 17 years with overweight or obesity, according to a study published onli…
Learn MoreReport IDs Those Likely to Receive Meds for Opioid Use Disorder in Pregnancy
THURSDAY, May 4, 2023 (HealthDay News) — Persons receiving medication for opioid use disorder (MOUD) in pregnancy are more likely to be older and White and to have public insurance, according to research published in the May 5 issue of the U.S. Cent…
Learn MoreTeen Dating Violence Is Risk Factor for Negative Long-Term Outcomes
THURSDAY, May 4, 2023 (HealthDay News) — Teen dating violence (TDV) in adolescence is a risk factor for negative long-term outcomes, according to a review published online May 2 in Pediatrics.Antonio Piolanti, Ph.D., from the University of Klagenfurt…
Learn MoreFDA Approves Lumryz for Narcolepsy
THURSDAY, May 4, 2023 (HealthDay News) — The U.S. Food & Drug Administration has approved Lumryz for the treatment of cataplexy or excessive daytime sleepiness in adults with narcolepsy. Lumryz is an extended-release formulation of sodium oxybate to…
Learn More